Application value of ESAT-6 combined with MMP-9 in assessing the severity of tuberculosis destroyed lung

doi:10.3969/j.issn.1000-6621.2021.02.007

Abstract

Abstract:

Objective To explore the application value of early secretory antigen target-6 (ESAT-6) and matrix metalloproteinase-9 (MMP-9) in evaluating the severity of tuberculous damage to the lung. Methods From January 2018 to January 2019, 55 patients with tuberculosis-destroyed lung (group A), 40 patients with secondry tuberculosis pulmonary (group B) and 20 healthy volunteers with physical examination (group C) were selected from the Third People’s Hospital of Kunming. The clinical data and laboratory examination results were collected, and the level (M(Q₁,Q₃)) of ESAT-6, MMP-9 and immune function were compared among the groups. Results The expression level of ESAT-6 were 28.83 (19.26, 38.20) pg/ml in group A, 22.26 (17.85, 25.01) pg/ml in group B, which were both significantly higher than that in group C (0.06 (0.03, 1.50) pg/ml; U=63.155, P<0.01; U=49.725, P<0.01). The expression level of MMP-9 in group A was 12.54 (9.01, 18.11) μg/ml, which was significantly higher than those in group B (6.80 (4.10, 12.29) μg/ml) and group C (1.14 (0.72, 1.29) μg/ml; U=26.097, P<0.01; U=66.309, P<0.01). The expression level of ESAT-6 in pulmonary tuberculosis patients (group A and group B) was 24.05 (18.54, 34.89) pg/ml, which was negatively correlated with the count of CD4⁺ T lymphocytes (476.00 (312.00, 647.00) cells/μl and CD3⁺ T lymphocytes (599.00 (456.00, 762.00) cells/μl; r=-0.462, P<0.01; r=-0.275, P=0.003). The expression of MMP-9 was 11.05 (6.30, 14.28) μg/ml, which was negatively correlated with the count of CD4⁺ and CD3⁺ T lymphocytes (r=-0.499, P<0.01; r=-0.341, P<0.01). In group A, the expression of MMP-9 (10.79 (7.10, 12.54) μg/ml) in moderate and severe ventilatory dysfunction patients (52.7%, 29/55) was significantly lower than that in very severe ventilatory dysfunction patients (47.3% (26/55); 17.39 (12.47, 33.30) μg/ml; U=150.000, P<0.01). Conclusion The expression of ESAT-6 and MMP-9 increased in pulmonary tuberculosis patients, which was related to immune function. The level of MMP-9 was related to the severity of tuberculous damage to the destroyed lung.

Key words: Bacterial proteins, Matrix metalloproteinase 9, Tuberculosis,pulmonary, Evaluation studies

LU Ni-hong, SUN Ya-ping, JIN Yuan, XIA Jia-wei, YANG Yong-rui. Application value of ESAT-6 combined with MMP-9 in assessing the severity of tuberculosis destroyed lung[J]. Chinese Journal of Antituberculosis, 2021, 43(2): 139-142. doi: 10.3969/j.issn.1000-6621.2021.02.007

Figures/Tables 2

References 13

[1]	蒋良双, 吴邦贵, 龚胜, 等. 487例结核性毁损肺外科治疗的效果分析. 中国防痨杂志, 2018,40(12):1296-1301. doi: 10.3969/j.issn.1000-6621.2018.12.011.
[2]	Kosar A, Orki A, Kiral H, et al. Pneumonectomy in children for destroyed lung:evaluation of 18 cases. Ann Thorac Surg, 2010,89(1):226-231. doi: 10.1016/j.athoracsur.2009.10.007.
[3]	海杰. 全肺切除治疗低肺功能肺结核毁损肺患者的临床疗效研究. 世界最新医学信息文摘(连续型电子期刊), 2018,18(36):21-22. doi: 10.19613/j.cnki.1671-3141.2018.36.011.
[4]	蔡宝云, 张金福, 初乃惠, 等. 结核性毁损肺发生的相关因素分析. 中国防痨杂志, 2011,33(9):570-574.
[5]	中华人民共和国国家卫生和计划生育委员会. WS288—2017 肺结核诊断. 2017-11-09.
[6]	中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 常规肺功能检查基层指南(2018年). 中华全科医师杂志, 2019,18(6):511-518. doi: 10.3760/cma.j.issn.1671-7368.2019.06.003.
[7]	Bai L, Hong Z, Gong C, et al. Surgical treatment efficacy in 172 cases of tuberculosis-destroyed lungs. Eur J Cardiothorac surg, 2012,41(2):335-340. doi: 10.1016/j.ejcts.2011.05.028.
[8]	任国强, 李炳辉, 李恭驰, 等. 基质金属蛋白质酶-9与血管内皮生长因子在糖尿病血管生成中作用的研究进展. 感染、炎症、修复, 2019,20(1):59-62. doi: 10.3969/j.issn.1672-8521.2019.01.014.
[9]	Fan X, Wang E, Wang X, et al. MicroRNA-21 is a unique signature associated with coronary plaque instability in humans by regulating matrix metalloproteinase-9 via reversion-inducing cysteine-rich protein with Kazal motifs. Exp Mol Pathol, 2014,96(2):242-249. doi: 10.1016/j.yexmp.2014.02.009.
[10]	Mira E, Lacalle RA, Buesa JM, et al. Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J Cell Sci, 2004,117(Pt 9):1847-1850. doi: 10.1242/jcs.01035.
[11]	Kundu S, Pushpakumar SB, Tyagi A, et al. Hydrogen sulfide deficiency and diabetic renal remodeling: role of matrix metalloproteinase-9. Am J Physiol Endocrinol Metab, 2013,304(12):E1365-E1378. doi: 10.1152/ajpendo.00604.2012.
[12]	Soo C, Shaw WW, Zhang X, et al. Differential expression of matrix metalloproteinases and their tissue-derived inhibitors in cutaneous wound repair. Plast Reconstr Surg, 2000,105(2):638-647. doi: 10.1097/00006534-200002000-00024.
[13]	李昕辉. MMP-2,MMP-9联合外周血T淋巴细胞亚群的变化对肺癌侵袭和转移预测研究. 北华大学学报(自然科学版), 2014,15(2):197-200. doi: 10.11713/j.issn.1009-4822.2014.02.011.

临床特征	结核性毁损肺组(55例)	继发性肺结核组(40例)	χ²值	P值
肺通气功能障碍			4.881	0.027
中重度	29(52.7)	30(75.0)
极重度	26(47.3)	10(25.0)
结核球			10.482	0.001
有	35(63.6)	12(30.0)
无	20(36.4)	28(70.0)
肺外结核			0.062	0.804
有	15(33.3)	10(25.0)
无	40(66.7)	30(75.0)

组别	ESAT-6[pg/ml, M(Q₁,Q₃)]	MMP-9[μg/ml, M(Q₁,Q₃)]	T淋巴细胞计数[个/μl,M(Q₁,Q₃)]
组别	ESAT-6[pg/ml, M(Q₁,Q₃)]	MMP-9[μg/ml, M(Q₁,Q₃)]	CD4⁺	CD8⁺	CD3⁺
结核性毁损肺组(55例)	28.83 (19.26,38.20)	12.54 (9.01,18.11)	376.00 (257.00,577.00)	451.00 (327.00,547.00)	481.00 (424.00,574.00)
继发性肺结核组(40例)	22.26 (17.85,25.01)	6.80 (4.10,12.29)	597.00 (509.00,693.00)	651.50 (539.25,699.50)	761.00 (732.00,790.75)
健康志愿者组(20名)	0.06 (0.03,1.50)	1.14 (0.72,1.29)	908.50 (808.25,938.00)	649.00 (591.25,768.25)	1399.00 (1315.25,1492.75)
H值^a	52.896	59.715	58.816	39.103	76.235
P值^a	<0.01	<0.01	<0.01	<0.01	<0.01
U值^b	13.430	26.097	-27.734	-35.682	-36.466
P值^b	0.053	<0.01	<0.01	<0.01	<0.01
U值^c	63.155	66.309	-65.334	-44.107	-72.491
P值^c	<0.01	<0.01	<0.01	<0.01	<0.01
U值^d	49.725	40.213	-37.600	-8.425	-36.025
P值^d	<0.01	<0.01	<0.01	1.00	<0.01

[1]	KUANG Hao-bin, XIE Yu-hong, FENG Zhi-yu, QIN Hong-juan, LIAO Ya-yi, WANG Min, ZHANG Hong, YUANG Yuan, WU Di, CHEN Ze-ying, TAN Shou-yong. Analysis on the effect of management strategies for multidrug-resistant tuberculosis in Guangzhou from 2014-2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(2): 113-118.
[2]	CUI Xiao-jing, WEI Dong, WANG Chun-lei, CAO Bin. Value of molecular diagnosis and liquid culture methods in improving the pathogenic diagnosis of pulmonary tuberculosis in general hospitals [J]. Chinese Journal of Antituberculosis, 2021, 43(2): 143-146.
[3]	LIU Zhi-bin, WU Min, WU Xiao-cui, HAN Min, XIAO He-ping, ZHANG Qing. The value of PCR-reverse dot blot hybridization in detecting the drug resistance of Mycobacterium tuberculosis in sputum specimens of retreatment smear-positive pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(1): 47-51.
[4]	CHEN Feng-fang, MA Jun, HUANG Jin, YIN Hong-yun, SHA Wei, YANG Guang-hong, FENG Yong-hong. Preliminary study on establishing the diagnostic model for smear negative tuberculosis and stage Ⅰ/Ⅱ sarcoidosis with hilar/mediastinal lymphadenopathy and positive T-SPOT.TB results [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 832-837.
[5]	DUAN Li-ming, DING Chao, LIU Yu-gang, WEI Lin, GU Zhen-ning. Application value of video-assisted thoracoscopic surgery in the treatment of chronic tuberculous empyema [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 850-853.
[6]	CHEN Zhen-hua,LIU Bin-bin,CHEN Zhong-nan,TAN Yun-hong. Establishment and preliminary evaluation of a diagnostic model for the new patients with pathogen-negative pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 266-271.
[7]	MA Gai-xia,TIAN Li-ming,WANG Yu,QIU Lei,XUE Ling-na,LU Zhen-hui,ZHANG Hui-yong,GUO Xiao-yan. Systematic evaluation and meta-analysis of integrated traditional Chinese and western medicine in the treatment of MDR-PTB [J]. Chinese Journal of Antituberculosis, 2020, 42(2): 95-100.
[8]	GU Ji-xiu, LI Qing, MA ling, LI Yin-hua, WANG Dong-dong, SI Hong-yan. Application of next-generation sequencing technology in the diagnosis of drug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(11): 1203-1208.
[9]	WANG Ze-ming, SUN Lin, SHEN A-dong. Current status and thinking of clinical practice guidelines of tuberculosis in children [J]. Chinese Journal of Antituberculosis, 2020, 42(10): 1025-1028.
[10]	BAI Yun-song, ZHANG Xue-jun, CAO Jun, FENG Lei, QI Xin-yu, GUO Dong, YAO Zi-ming, LI Cheng-xin. Analysis of clinical efficacy of stageⅠanterior-posterior approach surgery for lumbar tuberculosis in children [J]. Chinese Journal of Antituberculosis, 2020, 42(10): 1048-1052.
[11]	MAO Yi, ZENG Yi-lan, WU Gui-hui, JIANG Zhi-hao, FAN Lin. Correlation analysis between clinical characteristics and flow cytometry cells subsets in peripheral blood of patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(10): 1080-1086.
[12]	NING Feng-gang,ZHOU Xin-hua,HOU Dai-lun,LYU Ping-xin,LYU Yan,HE Wei. MR imaging features of hematogeneous pulmonary tuberculosis accompanied with intracranial tuberculosis in adult patients [J]. Chinese Journal of Antituberculosis, 2020, 42(1): 19-25.
[13]	REN Hang-kong,DUAN Li-ming,ZHEN Qin-fang. The value of two techniques in detecting chest wall tuberculosis from different surgical specimens [J]. Chinese Journal of Antituberculosis, 2020, 42(1): 74-78.
[14]	Hong-wei ZHANG,Jing XU,Yu MA,Ya-li DENG. Evaluating the implementation effect of tuberculosis patients health management services for Basic Public Health Projects in Shaanxi Province [J]. Chinese Journal of Antituberculosis, 2019, 41(9): 951-956.
[15]	Xi CHEN,Zhong-quan LIU,Bin WANG,Hui ZHU,Lei FU,Yuan-yuan LI,Yu LU. Evaluation of antituberculosis activities of 14 antituberculosis drugs in macrophage [J]. Chinese Journal of Antituberculosis, 2019, 41(9): 993-998.